-transparent.png){kind=logo}
Auditory neurotoxicity occurred in 13 (26%) of 50 evaluable patients receiving long term desferrioxamine chelation. In five of these patients, all of whom were receiving high doses of desferrioxamine, the toxicity caused deafness. These five patients were treated with subcutaneous calcium diethylene triamine pentacetic acid (Ca-DTPA) with zinc supplements instead of desferrioxamine, and their hearing improved during periods of seven to 19 months. Their serum ion concentrations remained unchanged. We suggest that all patients receiving long term desferrioxamine should have audiometric assessments at 6-12 monthly intervals. Ca-DTPA with oral zinc supplements should be considered as alternative to desferrioxamine as an iron chelating treatment in patients with auditory neurotoxicity.
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
July 1989,
Clinical nephrology,
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
April 1988,
Clinical nephrology,
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
November 1981,
Lancet (London, England),
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
March 1977,
Health physics,
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
December 1978,
Health physics,
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
October 2021,
Cancers,
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
January 1965,
La Presse medicale,
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
May 1967,
Nederlands tijdschrift voor geneeskunde,
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
October 1976,
Teratology,
B Wonke, and
A V Hoffbrand, and
M Aldouri, and
D Wickens, and
D Flynn, and
M Stearns, and
P Warner
November 1975,
Lancet (London, England),
